Scroll
Dedicated to redefining therapeutic possibilities for neurodevelopmental conditions.
Confluence's mission is to advance all research in Autism and Fragile X Syndrome and bring to market a solution that treats core social and communication impairments.
We understand the profound impact of being able to communicate and socially interact has on everyday life. We want to change the way people think about treating Fragile X and Autism — and how they will administer or direct therapies in the future.
Novel
Therapeutic Approach
Confluence is developing novel, clinically-discovered therapeutic treatments for core social and communication impairments caused by Fragile X Syndrome, Autism, and other similarly anchored disorders.
Improving talking, thinking, social interaction, and self-care capabilities.
Grounded in rigorous scientific research and validated clinical observations.
Every decision is guided by the needs of patients and their families.
Advancing novel therapeutics through rigorous clinical development to address the unmet needs of neurodevelopmental, neuropsychiatric, and addiction-related disorders.
A sustained-release sprinkle formulation designed to improve communication, social behavior, attention, anxiety, and hyperactivity across multiple neurodevelopmental and neuropsychiatric indications.
Treatment of pediatric and adult patients by improving communications, social behavior, attention, anxiety, and hyperactivity.
Treatment of pediatric and adult patients by improving communications, social behavior, attention, anxiety, and hyperactivity.
Maintenance of alcohol abstinence.
Identification of responders/non-responders and patients responding to treatment.
Treatment of adolescent and adult patients for anxiety.
Completed
Preclinical Development
In vitro & in vivo validation
Phase II Ready
Safety & Efficacy Trials
Patient population studies
A combination sustained-release approach targeting enhanced communication, attention, memory, and learning across neurodevelopmental and addiction-related conditions.
Combination treatment improves communication, attention, memory, and learning.
Combination treatment improves communication, attention, memory, and learning.
Combination treatment improves communication, attention, and memory.
0
Individuals with Fragile X
0
Million with Autism
0
FDA-Approved Treatments
1
Dedicated Mission
Despite affecting millions worldwide, there remains no FDA-approved pharmacological treatment that directly addresses the core social and communication deficits in Fragile X Syndrome and Autism. Confluence is working to change that.
Founded by scientists and clinicians with deep expertise in neurodevelopmental biology and drug development.
President & Founder
President & Founder with decades of experience in business leadership and drug development.
Lead Scientific Advisor
World-renown expert in neurodevelopment biology guiding Confluence's scientific strategy.
Chairman & Founder
Chairman & Founder with decades of experience in the commercializing mental health services, engaging mental health advocates and consumer groups.
Vice President of Corporate Affairs
25+ years experience in global healthcare strategy, marketing and business development; Director of Strategic Marketing at both Guidant and Eli Lilly.
Director of CM&C
15+ years experience developing large and small molecule CM&C programs (Chorus Europe–Vanthys Pharmaceutical–Eli Lilly).
Clinical Pharmacology Advisor
25+ years pharmaceutical experience in designing and executing early clinical development programs for central nervous system (CNS), cardiovascular (CV), and gastrointestinal (GI) drugs (Astellas, Pfizer, Lederle, Berlex).
Dr. Michael Aman
Ohio State
Dr. Len Abbeduto
MIND Institute UC-Davis
Dr. Elizabeth Berry-Kravis
Rush University MC
Dr. Brian King
University of California-San Francisco, Weill Institute for Neurosciences
Dr. Lauren Schmitt
Cincinnati Children's Hospital MC
Dr. Don Bailey
RTI International
We are actively seeking collaborations with research institutions, patient advocacy groups, and strategic partners who share our vision.